Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease?

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2016 Jun 1

PMID 27242726

Citations 7

Authors

Alexandre Morrot

Silvina R Villar

Florencia B Gonzalez

Ana R Perez

Affiliations

Soon will be listed here.

Abstract

Chagas disease is a serious illness caused by the protozoan parasite Trypanosoma cruzi. Nearly 30% of chronically infected people develop cardiac, digestive, or mixed alterations, suggesting a broad range of host-parasite interactions that finally impact upon chronic disease outcome. The ability of T. cruzi to persist and cause pathology seems to depend on diverse factors like T. cruzi strains, the infective load and the route of infection, presence of virulence factors, the parasite capacity to avoid protective immune response, the strength and type of host defense mechanisms and the genetic background of the host. The host-parasite interaction is subject to a constant neuro-endocrine regulation that is thought to influence the adaptive immune system, and as the infection proceeds it can lead to a broad range of outcomes, ranging from pathogen elimination to its continued persistence in the host. In this context, T. cruzi evasion strategies and host defense mechanisms can be envisioned as two sides of the same coin, influencing parasite persistence and different outcomes observed in Chagas disease. Understanding how T. cruzi evade host's innate and adaptive immune response will provide important clues to better dissect mechanisms underlying the pathophysiology of Chagas disease.

Citing Articles

IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease.

Serrano I, Ribeiro G, Santos R, Cruz J, Lanza F, Santos E Am J Trop Med Hyg. 2024; 110(4):669-676.

PMID: 38412539 PMC: 10993828. DOI: 10.4269/ajtmh.23-0652.

Central nervous system commitment in Chagas disease.

Useche Y, Perez A, de Meis J, Bonomo A, Savino W Front Immunol. 2022; 13:975106.

PMID: 36439149 PMC: 9685529. DOI: 10.3389/fimmu.2022.975106.

Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against .

Gamba J, Roldan C, Prochetto E, Lupi G, Bontempi I, Poncini C Front Cell Infect Microbiol. 2021; 11:671104.

PMID: 34295832 PMC: 8290872. DOI: 10.3389/fcimb.2021.671104.

Functional Autoreactive Anti-β2 Adrenergic Antibodies May Contribute to Insulin Resistance Profile in Patients with Chronic Chagas Disease.

Rodeles L, Vicco M, Siano A, Fuchs L, Peverengo L, Puch S Pathogens. 2021; 10(3).

PMID: 33801107 PMC: 8004215. DOI: 10.3390/pathogens10030378.

The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Acevedo G, Girard M, Gomez K Front Immunol. 2018; 9:1929.

PMID: 30197647 PMC: 6117404. DOI: 10.3389/fimmu.2018.01929.

References

Villar S, Ronco M, Fernandez Bussy R, Roggero E, Lepletier A, Manarin R . Tumor necrosis factor-α regulates glucocorticoid synthesis in the adrenal glands of Trypanosoma cruzi acutely-infected mice. the role of TNF-R1. PLoS One. 2013; 8(5):e63814. PMC: 3661674. DOI: 10.1371/journal.pone.0063814. View

Ramos S, Rossi M . Microcirculation and Chagas' disease: hypothesis and recent results. Rev Inst Med Trop Sao Paulo. 1999; 41(2):123-9. DOI: 10.1590/s0036-46651999000200011. View

Nagajyothi F, Machado F, Burleigh B, Jelicks L, Scherer P, Mukherjee S . Mechanisms of Trypanosoma cruzi persistence in Chagas disease. Cell Microbiol. 2012; 14(5):634-43. PMC: 3556388. DOI: 10.1111/j.1462-5822.2012.01764.x. View

Watson S, Miller T, Redington T, Bullock W . Immunoregulation in experimental disseminated histoplasmosis: flow microfluorometry (FMF) studies of the Thy and Lyt phenotypes of T lymphocytes from infected mice. J Immunol. 1983; 131(2):984-90. View

Zhang L, Tarleton R . Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis. 1999; 180(2):480-6. DOI: 10.1086/314889. View

Schenkman S, Jiang M, Hart G, NUSSENZWEIG V . A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell. 1991; 65(7):1117-25. DOI: 10.1016/0092-8674(91)90008-m. View

Tambourgi D, Kipnis T, da Silva W, Joiner K, Sher A, Heath S . A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF. Infect Immun. 1993; 61(9):3656-63. PMC: 281061. DOI: 10.1128/iai.61.9.3656-3663.1993. View

Chen W, KuoLee R, Austin J, Shen H, Che Y, Conlan J . Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. Microb Pathog. 2005; 39(5-6):189-96. PMC: 1564440. DOI: 10.1016/j.micpath.2005.08.005. View

Padilla A, Simpson L, Tarleton R . Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol. 2009; 183(2):1245-52. DOI: 10.4049/jimmunol.0901178. View

10.

Correa-de-Santana E, Pinto-Mariz F, Savino W . Immunoneuroendocrine interactions in Chagas disease. Ann N Y Acad Sci. 2006; 1088:274-83. DOI: 10.1196/annals.1366.005. View

11.

Elias F, Vigliano C, Laguens R, Levin M, Berek C . Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. Am J Trop Med Hyg. 2003; 68(2):242-7. View

12.

Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

13.

Radomski M, Buguet A, Doua F, Bogui P, TAPIE P . Relationship of plasma growth hormone to slow-wave sleep in African sleeping sickness. Neuroendocrinology. 1996; 63(4):393-6. DOI: 10.1159/000126980. View

14.

Schenkman S, Eichinger D, Pereira M, NUSSENZWEIG V . Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol. 1994; 48:499-523. DOI: 10.1146/annurev.mi.48.100194.002435. View

15.

Kierszenbaum F, Fresno M, Sztein M . The Trypanosoma cruzi membrane glycoprotein AGC10 inhibits human lymphocyte activation by a mechanism preceding translation of both, interleukin-2 and its high-affinity receptor subunits. Mol Biochem Parasitol. 2002; 125(1-2):91-101. DOI: 10.1016/s0166-6851(02)00217-7. View

16.

Besedovsky H, Del Rey A . Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996; 17(1):64-102. DOI: 10.1210/edrv-17-1-64. View

17.

Engman D, Leon J . Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop. 2002; 81(2):123-32. DOI: 10.1016/s0001-706x(01)00202-9. View

18.

Maleckar J, Kierszenbaum F . Inhibition of mitogen-induced proliferation of mouse T and B lymphocytes by bloodstream forms of Trypanosoma cruzi. J Immunol. 1983; 130(2):908-11. View

19.

DosReis G . Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res. 2011; 44(2):84-90. DOI: 10.1590/s0100-879x2011007500005. View

20.

Girones N, Cuervo H, Fresno M . Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr Top Microbiol Immunol. 2005; 296:89-123. DOI: 10.1007/3-540-30791-5_6. View